Article Details
Retrieved on: 2024-04-02 23:06:19
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Snell & Wilmer's representation of Trawsfynydd Therapeutics in its merger with Onconova Therapeutics, focusing on antiviral development for COVID-19 and targeting financial markets and investment through equity securities like NASDAQ.
Article found on: www.swlaw.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here